Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.31|
|52 Week High||AU$0.17|
|52 Week Low||AU$0.45|
|1 Month Change||5.09%|
|3 Month Change||-3.13%|
|1 Year Change||31.92%|
|3 Year Change||-21.52%|
|5 Year Change||-34.04%|
|Change since IPO||-48.33%|
Recent News & Updates
|MX1||AU Medical Equipment||AU Market|
Return vs Industry: MX1 exceeded the Australian Medical Equipment industry which returned -4.9% over the past year.
Return vs Market: MX1 exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: MX1 is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: MX1's weekly volatility (8%) has been stable over the past year.
About the Company
Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. The company offers mobile digital radiology products, including Rover, an integrated and digital x-ray system for bedside imaging in hospitals and temporary medical facilities, as well as military and veterinary applications; and Carestream DRX Revolution Nano, a mobile x-ray imaging product for OEMs. It also develops X-Ray camera for security imaging of improvised explosive devices; airport checkpoint portal with self-service x-ray; and miniature brain CT imager for pre-hospital stroke diagnosis in ambulances.
Micro-X Fundamentals Summary
|MX1 fundamental statistics|
Is MX1 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MX1 income statement (TTM)|
|Cost of Revenue||AU$5.14m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.032|
|Net Profit Margin||-390.64%|
How did MX1 perform over the long term?See historical performance and comparison
Is Micro-X undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MX1's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MX1's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MX1 is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: MX1 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MX1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MX1 is good value based on its PB Ratio (4.2x) compared to the AU Medical Equipment industry average (4.5x).
How is Micro-X forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MX1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: MX1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MX1's is expected to become profitable in the next 3 years.
Revenue vs Market: MX1's revenue (61.1% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: MX1's revenue (61.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MX1's Return on Equity is forecast to be high in 3 years time (24.5%)
How has Micro-X performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MX1 is currently unprofitable.
Growing Profit Margin: MX1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MX1 is unprofitable, but has reduced losses over the past 5 years at a rate of 2.4% per year.
Accelerating Growth: Unable to compare MX1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MX1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: MX1 has a negative Return on Equity (-43.06%), as it is currently unprofitable.
How is Micro-X's financial position?
Financial Position Analysis
Short Term Liabilities: MX1's short term assets (A$35.8M) exceed its short term liabilities (A$4.3M).
Long Term Liabilities: MX1's short term assets (A$35.8M) exceed its long term liabilities (A$6.2M).
Debt to Equity History and Analysis
Debt Level: MX1 is debt free.
Reducing Debt: MX1 has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MX1 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MX1 has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 4% each year.
What is Micro-X current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MX1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MX1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MX1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MX1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MX1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Peter Robin Rowland, BSc., MBA, MIET, CEng, FAICD, serves as Managing Director, Executive Director and Chief Executive Officer of Micro-X Limited. Mr. Rowland is a laser industry veteran with experienc...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD527.92K) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
Experienced Management: MX1's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: MX1's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.8%.
Micro-X Limited's employee growth, exchange listings and data sources
- Name: Micro-X Limited
- Ticker: MX1
- Exchange: ASX
- Founded: 2011
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$142.640m
- Shares outstanding: 460.13m
- Website: https://www.micro-x.com
- Micro-X Limited
- A14, 6 MAB Eastern Promenade
- 1284 South Road
- South Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:37|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.